RT Journal Article
SR Electronic
A1 Boltz, Kathy
T1 ASSESS
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 8
SP 7
OP 8
DO 10.1177/1559897715588497
UL http://mdc.sagepub.com/content/15/8/7.abstract
AB EGFR mutations can be analyzed with circulating tumor DNA, with an overall concordance of EGFR mutation status of 89%. The low positive predictive value of 78% was likely due to false-negative tumor samples using less sensitive methodologies such as DNA sequencing or pyrosequencing, and it increased to 93% when highly sensitive methods such as the QIAGEN Therascreen RGQ PCR kit was used for both tissue/cytology samples and plasma samples.